Glenmark Pharma’s innovation arm signs exclusive licensing agreement with AbbVie for ISB 2001

On the road ahead, Glenmark MD & CEO Glenn Saldana said that the roadmap would be to IPO IGI in the future and that the unit is self funded for at least the next three years if not more.

Leave a Reply

Your email address will not be published. Required fields are marked *